Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
New clinical trial designs for establishing drug efficacy and safety in a precision medicine era.
Journal: Diabetes, obesity & metabolism
Published: May 29, 2018
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
Journal: Metabolism: clinical and experimental
Published: November 06, 2017
Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes.
Journal: Diabetes & vascular disease research
Published: May 27, 2015
Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
Journal: Diabetic medicine : a journal of the British Diabetic Association
Published: November 04, 2014
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Journal: Diabetes care
Published: October 02, 2014
Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.
Journal: Diabetes technology & therapeutics
Published: November 19, 2013
Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Journal: Clinical therapeutics
Published: September 16, 2013
Effects of dapagliflozin on cardiovascular risk factors.
Journal: Postgraduate medicine
Published: June 11, 2013
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
Journal: Kidney international
Published: April 25, 2013
Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.
Journal: Diabetes research and clinical practice
Published: March 19, 2013
Last Updated: 09/26/2026